Full Press Release Details
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting.
BIIB
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
Key Takeaway: Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
Price reaction · baseline $208.57 (2022-03-18 close) · clean, no other BIIB news in the window
day 0 close · peak
-0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis